Bosh sahifaADAP • NASDAQ
add
Adaptimmune Therapeutics PLC - ADR
Yopilish kursi
0,62 $
Kunlik diapazon
0,57 $ - 0,63 $
Yillik diapazon
0,53 $ - 2,05 $
Bozor kapitalizatsiyasi
158,62 mln USD
Oʻrtacha hajm
2,43 mln
Asosiy maydon
NASDAQ
Bozor yangiliklari
Moliyaviy axborot
Moliyaviy hisobot
Daromad
Sof foyda
| (USD) | sen, 2024info | Y/Y qiyosi |
|---|---|---|
Daromad | 40,90 mln | 458,83% |
Joriy xarajat | 21,28 mln | 31,63% |
Sof foyda | -17,62 mln | 61,37% |
Sof foyda marjasi | -43,07 | 93,09% |
Har bir ulushga tushum | -0,01 | 70,15% |
EBITDA | -11,86 mln | 72,88% |
Amaldagi soliq stavkasi | -4,95% | — |
Balans
Jami aktivlari
Jami passivlari
| (USD) | sen, 2024info | Y/Y qiyosi |
|---|---|---|
Naqd pul va qisqa investitsiyalar | 186,09 mln | 15,06% |
Jami aktivlari | 317,44 mln | 7,01% |
Jami passivlari | 237,45 mln | 13,88% |
Umumiy kapital | 79,99 mln | — |
Tarqatilgan aksiyalar | 255,88 mln | — |
Narxi/balansdagi bahosi | 2,00 | — |
Aktivlardan daromad | -11,48% | — |
Kapitaldan daromad | -24,62% | — |
Pul aylanmasi
Naqd pulning sof oʻzgarishi
| (USD) | sen, 2024info | Y/Y qiyosi |
|---|---|---|
Sof foyda | -17,62 mln | 61,37% |
Operatsiyalardan naqd pul | -54,45 mln | -20,58% |
Sarmoyadan naqd pul | -66,02 mln | -215,20% |
Moliyadan naqd pul | 25,00 mln | 4 094,80% |
Naqd pulning sof oʻzgarishi | -95,25 mln | -840,01% |
Boʻsh pul | -41,07 mln | -62,70% |
Haqida
Adaptimmune is a biopharmaceutical company that develops T cell therapies against cancer. The company was founded in 2008 in the UK with links to both Oxford University and the University of Pennsylvania. It has headquarters in Philadelphia and Milton Park. In August 2024, the US Food and Drug Administration granted accelerated approval to Adaptimmune's Tecelra, a therapy against a rare form of cancer. Tecelra is the first T cell therapy to be approved for use against a solid tumor. Wikipedia
Tashkil etilgan
2008
Sayt
Xodimlar soni
449
